Janux Therapeutics Inc (NASDAQ: JANX) kicked off on Tuesday, up 4.58% from the previous trading day, before settling in for the closing price of $50.49. Over the past 52 weeks, JANX has traded in a range of $5.65-$65.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 32.66% over the last five years. While this was happening, its average annual earnings per share was recorded 13.65%. With a float of $38.94 million, this company’s outstanding shares have now reached $46.25 million.
The firm has a total of 64 workers. Let’s measure their productivity. In terms of profitability, gross margin is 86.32%, operating margin of -435.86%, and the pretax margin is -291.17%.
Janux Therapeutics Inc (JANX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 25.35%, while institutional ownership is 81.11%. The most recent insider transaction that took place on Oct 18 ’24, was worth 53,700,000. In this transaction Director of this company bought 1,200,000 shares at a rate of $44.75, taking the stock ownership to the 9,317,246 shares. Before that another transaction happened on Oct 21 ’24, when Company’s FORMER OFFICER proposed sale 10,769 for $49.43, making the entire transaction worth $532,310.
Janux Therapeutics Inc (JANX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.25 earnings per share (EPS), higher than consensus estimate (set at -0.47) by 0.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.65% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Take a look at Janux Therapeutics Inc’s (JANX) current performance indicators. Last quarter, stock had a quick ratio of 57.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 182.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.92, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.61 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Analysing the last 5-days average volume posted by the [Janux Therapeutics Inc, JANX], we can find that recorded value of 0.64 million was lower than the volume posted last year of 0.71 million. As of the previous 9 days, the stock’s Stochastic %D was 78.81%. Additionally, its Average True Range was 2.76.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 85.11%, which indicates a significant decrease from 96.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.60% in the past 14 days, which was lower than the 61.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.21, while its 200-day Moving Average is $38.96. Now, the first resistance to watch is $53.98. This is followed by the second major resistance level at $55.15. The third major resistance level sits at $57.28. If the price goes on to break the first support level at $50.68, it is likely to go to the next support level at $48.55. Now, if the price goes above the second support level, the third support stands at $47.38.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
The company with the Market Capitalisation of 2.75 billion has total of 51,851K Shares Outstanding. Its annual sales at the moment are 8,080 K in contrast with the sum of -58,290 K annual income. Company’s last quarter sales were recorded 8,900 K and last quarter income was -5,960 K.
